Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Hyperaldosteronism: later-stage trial registry
2 of 2 indexed Primary Hyperaldosteronism trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Primary Hyperaldosteronism: 2 US clinical trials tracked, 2 recruiting.
Primary Hyperaldosteronism is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Duke University, running 1 of these trials.
Enrollment posture brief
Registry condition primary-hyperaldosteronism
OPEN 2 | RECR 100% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Primary Hyperaldosteronism lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Hyperaldosteronism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Hyperaldosteronism is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Duke University
NCT04278404
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
AstraZeneca
NCT07007793
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Hyperaldosteronism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Hyperaldosteronism trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Hyperaldosteronism page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Primary Hyperaldosteronism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Duke University sponsors the most Primary Hyperaldosteronism trials on record, review their full trial history before evaluating a specific study. See Duke University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Hyperaldosteronism condition card totals 2 registered trials; most-linked intervention The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.